Anavex Life Sciences (AVXL) has formally asked the European Medicines Agency to re-examine its opinion made earlier in ...
Zacks Investment Research on MSN
SNY's rare disease drug Efdoralprin Alfa gets EMA's orphan drug tag
Sanofi SNY announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (“ODD”) to efdoralprin alfa ...
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the ...
PRESS RELEASE Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European UnionOrphan designation confers market exclusivity, ...
ImmunityBio Inc. (NASDAQ: IBRX) is one of the best multibagger penny stocks to buy right now. On December 12, analysts at ...
Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. -- Vir Biotechnology's chronic hepatitis delta ...
On the same day, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive ...
Although development of a jab for the H5N1 strain of avian flu is well under way, other strains are receiving less attention ...
EU Reaches Landmark Deal On Pharma Package. Legal News and Analysis - EU, Europe - Regulatory & Compliance - Conventus Law ...
Sanofi (EURONEXT: SAN) announced Wednesday that its investigational therapy, efdoralprin alfa, has received orphan drug ...
Grifols S.A. has received certification from the European Medicines Agency (EMA) for the entire value chain of Grifols Egypt ...
Anavex had proposed restricting the drug's indication to patients with early Alzheimer's without mutations in the SIGMAR1 gene.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback